Entera Bio Analyst Ratings
Entera Bio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/11/2023 | 1487.3% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/08/2023 | 1487.3% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 04/04/2023 | 1487.3% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 03/28/2023 | 1487.3% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 09/06/2022 | 1487.3% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/19/2022 | 693.65% | B. Riley Securities | $6 → $5 | Maintains | Buy |
| 06/16/2021 | 1328.57% | B. Riley Securities | → $9 | Initiates Coverage On | → Buy |
| 03/22/2021 | 1804.76% | Aegis Capital | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/11/2023 | 1487.3% | HC Wainwright & Co. | → 10 美元 | 重申 | 購買 → 購買 |
| 05/08/2023 | 1487.3% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 04/04/2023 | 1487.3% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 03/28/2023 | 1487.3% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 09/06/2022 | 1487.3% | HC Wainwright & Co. | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 7 月 19 日 | 693.65% | B. 萊利證券 | 6 美元 → 5 美元 | 維護 | 購買 |
| 06/16/2021 | 1328.57% | B. 萊利證券 | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/22/2021 | 1804.76% | 宙斯盾資本 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Entera Bio (ENTX)?
Entera Bio（ENTX）的目標價格是多少？
The latest price target for Entera Bio (NASDAQ: ENTX) was reported by HC Wainwright & Co. on September 11, 2023. The analyst firm set a price target for $10.00 expecting ENTX to rise to within 12 months (a possible 1487.30% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年9月11日公佈了Entera Bio（納斯達克股票代碼：ENTX）的最新目標股價。該分析公司將目標股價定爲10.00美元，預計ENTX將在12個月內上漲至12個月內（可能上漲1487.30％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Entera Bio (ENTX)?
Entera Bio（ENTX）的最新分析師評級是多少？
The latest analyst rating for Entera Bio (NASDAQ: ENTX) was provided by HC Wainwright & Co., and Entera Bio reiterated their buy rating.
HC Wainwright & Co. 對Entera Bio（納斯達克股票代碼：ENTX）的最新分析師評級由HC Wainwright & Co. 提供，Entera Bio重申了買入評級。
When is the next analyst rating going to be posted or updated for Entera Bio (ENTX)?
Entera Bio（ENTX）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entera Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entera Bio was filed on September 11, 2023 so you should expect the next rating to be made available sometime around September 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Entera Bio的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Entera Bio的最後一次評級是在2023年9月11日提交的，因此你應該預計下一個評級將在2024年9月11日左右公佈。
Is the Analyst Rating Entera Bio (ENTX) correct?
分析師對Entera Bio（ENTX）的評級是否正確？
While ratings are subjective and will change, the latest Entera Bio (ENTX) rating was a reiterated with a price target of $0.00 to $10.00. The current price Entera Bio (ENTX) is trading at is $0.63, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Entera Bio（ENTX）評級，目標股價爲0.00美元至10.00美元。Entera Bio（ENTX）的當前交易價格爲0.63美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。